Figure 3

mCD14 is decreased on monocytes from patients with ALS and correlates with disease burden and disease progression rate. (A) CD14^−/low/CD16⁺ monocytes were decreased in the total PBMC samples of all patients with ALS compared with HC (*p = 0.04). Fast progressing patients had reduced numbers of CD14^−/low/CD16⁺ monocytes in their PBMC (**p = 0.016). (B) CD14^−/low/CD16⁺ monocytes were decreased in fast progressing patients compared with slowly progressing patients (**p < 0.001) and HC (^##p < 0.001). (C) Fast (**p < 0.01) and slowly (*p < 0.01) progressing ALS had reduced CD14 protein signal on surface of their CD14⁺/CD16^˗ monocytes than HC. (D) CD14 MFI was decreased on CD14⁺/CD16⁻ and CD14⁺/CD16⁺ monocytes from patients with fast progressing ALS (**p < 0.01) compared with slowly progressing patients with ALS and HC (*p < 0.01). (E) CD14^−/low/CD16⁺ monocytes were negatively correlated with disease burden. (F) CD14^−/low/CD16⁺ monocytes were negatively correlated with rates of disease progression. (G) CD14^−/low/CD16⁺/TIM-3⁺ monocytes were increased in PBMC of fast progressing patients compared with CD14^−/low/CD16⁺/TIM-3⁺ monocytes from slowly progressing patients (^#p < 0.001) and HC (*p < 0.001). (H) CD14^−/low/CD16⁺/TIM-3⁺ monocytes were increased in fast progressing patients compared with slowly progressing patients (^##p < 0.001) and HC (**p < 0.001). (I) CD14^−/low/CD16⁺/TIM-3⁺ monocytes positively correlated with disease progression rates. (J) CD14^−/low/CD16⁺/TIM-3⁺ monocytes positively correlated with burden of disease.